ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
11.24
-0.54 (-4.58%)
At close: Feb 21, 2025, 4:00 PM
11.21
-0.03 (-0.27%)
After-hours: Feb 21, 2025, 5:53 PM EST
ARS Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ARS Pharmaceuticals stock have an average target of 26, with a low estimate of 19 and a high estimate of 30. The average target predicts an increase of 131.32% from the current stock price of 11.24.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 14, 2025.
Analyst Ratings
The average analyst rating for ARS Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Strong Buy Maintains $26 → $28 | Strong Buy | Maintains | $26 → $28 | +149.11% | Jan 14, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $26 → $27 | Buy | Maintains | $26 → $27 | +140.21% | Jan 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +166.90% | Oct 8, 2024 |
| Leerink Partners | Leerink Partners | Buy Maintains $21 → $25 | Buy | Maintains | $21 → $25 | +122.42% | Sep 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +166.90% | Sep 16, 2024 |
Financial Forecast
Revenue This Year
20.67M
from 30.00K
Increased by 68,783.33%
Revenue Next Year
124.79M
from 20.67M
Increased by 503.87%
EPS This Year
-0.59
from -0.57
EPS Next Year
-0.36
from -0.59
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 62.0M | 202.1M | 319.0M | |||
| Avg | 20.7M | 124.8M | 219.9M | |||
| Low | 5.9M | 80.5M | 151.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 206,646.7% | 878.1% | 155.7% | |||
| Avg | 68,783.3% | 503.9% | 76.2% | |||
| Low | 19,500.0% | 289.6% | 21.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.17 | 0.63 | 0.91 | |||
| Avg | -0.59 | -0.36 | 0.05 | |||
| Low | -0.74 | -1.18 | -0.74 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.